Furthermore, the clinical viability of JAK2 PROTACs is yet to be determined and, in the absence of PROTAC ligands specific for mutant-JAK2 or JAK2 fusions, JAK2 PROTACS may induce anemia and thrombocytopenia due to degradation of WT JAK2, therefore, further investigations are required. This evidence concerns the gene JAK2 and anemia (phenotype).